yahoo.com
May 20, 2008
NEWTON, Mass.----Pro-Pharmaceuticals, Inc. , a developer of first-in-class, carbohydrate-based targeted therapeutic compounds to treat cancer and liver fibrosis, today announced the American Stock Exchange notified the Company that it does not meet a continued listing standard because it has less...
[read full story]